Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings bioMérieux: Strengths and Weaknesses

  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: bioMérieux
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: bioMérieux
  • With a 2025 P/E ratio at 23.93 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company's enterprise value to sales, at 2.58 times its current sales, is high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

bioMérieux SectorFrance

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

bioMérieux SectorFrance

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

bioMérieux SectorFrance

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

bioMérieux SectorFrance

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

bioMérieux SectorFrance

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
12.9B
A
13.51B -
AA
- -
5.92B
BBB
5.82B - - - - -
4.6B
BBB
-
4.59B
BBB
2.99B
CCC
-
2.51B - - - - - - -
2.31B -
BBB
- -
1.76B - - - - - -
Average 5.69B
A
Weighted average by Cap.
A